Key facts
- Phase 2 tested 1, 3, 6 and 9 mg once weekly by injection under the skin, plus two escalation arms (6 to 9 mg and 3 to 6 to 9 mg).[1]
- Phase 1 single doses ranged from 0.04 mg to 12 mg; the 12-week phase 1 used 1.2 to 12 mg weekly without escalation.[3][4]
- Weight loss rose with dose: 9.5% at 1 mg up to 20.1% at 9 mg after 48 weeks.[2]
- Phase 3 (ENLIGHTEN) tests four doses, listed only as Dose 1 to Dose 4 on ClinicalTrials.gov.[6]
- This page reports trial protocols. It is not dosing advice, and eloralintide is not approved for any use.
Eloralintide Doses in the Phase 2 Trial
The 48-week phase 2 trial gave eloralintide once weekly at fixed doses of 1, 3, 6 or 9 mg, or escalated from 6 to 9 mg or from 3 to 6 to 9 mg, by subcutaneous injection.[1]
| Arm | n | Weight change | Nausea |
|---|---|---|---|
| Placebo | 53 | -0.4% | 14% |
| 1 mg weekly | 28 | -9.5% | 11% |
| 3 mg weekly | 24 | -12.4% | 13% |
| 6 mg weekly | 28 | -17.6% | 64% |
| 9 mg weekly | 54 | -20.1% | 33% |
| 6 to 9 mg (escalated) | 24 | -19.9% | 54% |
| 3 to 6 to 9 mg (escalated) | 52 | -16.4% | 25% |
Lilly reports that GI side effects were lower with slower dose escalation and similar to placebo at 1 mg and 3 mg.[2] The 3 to 6 to 9 mg arm had less nausea (25%) than 6 mg started directly (64%).[1]
Eloralintide Doses in Phase 1
Phase 1 tested single doses from 0.04 mg to 12 mg in healthy adults, then once-weekly doses of 1.2, 3, 6 and 12 mg for 12 weeks without escalation.[3][4]
- Single ascending doses: 0.04, 0.12, 0.4, 1.2, 4 and 12 mg, 6 people per dose. One 12 mg dose cut weight by 4.4% at week 4.[3]
- Twelve-week multiple doses (n = 100): placebo-adjusted weight change of -2.6% at 1.2 mg, -8.9% at 3 mg, -8.5% at 6 mg and -11.3% at 12 mg.[4]
- Exposure rose in proportion to dose, and the about-two-week half-life gave steady levels with weekly dosing.[4]
Eloralintide Dosing Schedule
Every eloralintide trial so far has used once-weekly subcutaneous injections, supported by a human half-life of about 310 to 366 hours.[3][4]
In the EloraTZP phase 2b, eloralintide started at 1 mg or 3 mg and rose to 6 mg or 9 mg, with combination arms escalating every 4 weeks.[5]
Phase 3 Doses
The ENLIGHTEN phase 3 trials compare four eloralintide doses with placebo, but ClinicalTrials.gov lists them only as Dose 1 to Dose 4, so the exact phase 3 doses are not public.[6]
Research Vial Strengths
DBR Labs supplies eloralintide for laboratory research in 5 mg, 10 mg and 20 mg lyophilised vials.
Vial strength describes the amount of powder in the vial. It is not a dose. Our products are for research use only and are not for human or veterinary use. See the vials.
Frequently Asked Questions
What doses of eloralintide were used in trials?
Phase 2 used 1, 3, 6 and 9 mg once weekly, plus escalation arms of 6 to 9 mg and 3 to 6 to 9 mg. Phase 1 tested single doses from 0.04 to 12 mg and 12 weeks of 1.2 to 12 mg weekly.
How often is eloralintide given?
Once a week by injection under the skin, in every trial so far. Its half-life of about two weeks supports weekly dosing.
What dose of eloralintide gave the most weight loss?
In phase 2, 9 mg weekly gave the largest mean loss at 48 weeks (20.1%), closely followed by the 6 to 9 mg escalation arm (19.9%).
Is there an approved eloralintide dose?
No. Eloralintide is not approved anywhere, so there is no approved dose. This page reports trial protocols only and is not medical advice.
Sources
- Billings LK, et al. Eloralintide phase 2, 48-week trial. The Lancet 2025;406:2631-2643. DOI 10.1016/S0140-6736(25)02155-5
- Eli Lilly press release, 6 Nov 2025: eloralintide phase 2 results
- Briere DA, et al. Discovery and first-in-human study of eloralintide. Molecular Metabolism 2025;102:102271. DOI 10.1016/j.molmet.2025.102271
- Bhattachar S, et al. Eloralintide 12-week multiple-dose phase 1. Diabetes, Obesity and Metabolism 2026;28(4):2651-2660. DOI 10.1111/dom.70439
- Eli Lilly press release, 30 Sep 2026: EloraTZP (eloralintide + tirzepatide) phase 2b results
- ClinicalTrials.gov NCT07321886, ENLIGHTEN-1
For research use only. Not for human or veterinary consumption. This guide summarises published research for information only. It is not medical advice and does not describe any use of products sold on this site.